Navigation Links
Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference

WESTMINSTER, Colo., Sept. 4 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that Paul L. Berns, President and CEO, will present a corporate overview at the Bear Stearns 20th Annual Healthcare Conference in New York.

The Company's presentation will take place at 9:00 a.m. (Eastern) on Monday, September 10, 2007. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through September 21, 2007.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, for which the company expects to initiate a Phase 1 trial in patients with advanced solid tumors in the second half of 2007. For additional information, please visit the Company's website at

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward- looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... The ... as the Pistoia Alliance continues to drive to increase the organization’s impact on ... is focusing its vision and expanding its work in supporting pre-competitive collaboration in ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... announced that it has received a Phase I Small Business Innovative Research (SBIR) ... Institute of General Medical Sciences (NIGMS), will fund the development of a technique ...
(Date:10/13/2015)... TORONTO , Oct. 13, 2015  Generex Biotechnology Corporation ... entered into a non-binding Letter of Intent (LOI) with MediTemp ... has developed a proprietary cooling technology designed to improve sperm ... the United States and three million men ... 25 and 44 diagnosed as infertile.  For 42% of those ...
(Date:10/13/2015)... Jersey (PRWEB) , ... October 13, 2015 , ... ... enhance the educational opportunities for school age children in the areas of Science, ... for all sectors of the national economy, and the program aims to increase ...
Breaking Biology Technology:
(Date:9/30/2015)... YORK , Sept. 30, 2015  The global glucose ... billion for 2015. So says a new report on the ... diabetes management segment dominate the market, followed by continuous glucose ... publisher. Kalorama reports on the market for these products in its ... ...
(Date:9/28/2015)... Sept. 28, 2015 CLEAR, the ... its expedited traveler service is coming to ... travel, bringing a frictionless experience, serious speed ... "CLEAR offers our travelers an expedited ... said Jim Smith , Executive Director, ...
(Date:9/28/2015)... According to a new market ... (Scanner & Others), Application (Access Control & Others), Industry ... Geography Global - Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020, at a CAGR of 23.40% between ... data T ables and 66 Figures ...
Breaking Biology News(10 mins):